Stem Cells the Nephilim Chuck Missler 1 6
From:Jesus IsraelViews:0 0ratingsTime:10:01More inEducation
The rest is here:
Stem Cells the Nephilim Chuck Missler 1 6 - Video
SCMOM 2012_AlloSource
AlloSource, a non-profit organization, offers more than 200 types of precise bone, skin, soft-tissue and custom-machined allografts for use in life-saving and life-enhancing medical procedures. The world #39;s leader in fresh cartilage tissue and skin allografts, the company developed a cleansing process for fresh tissue grafts that does not destroy live cells. Most recently, AlloSource created a technique to recover mesenchymal stem cells from cadaveric adipose tissue, which led to the development of its own stem cell product, AlloStem® Stem Cell Bone Growth Substitute. AlloSource is registered with the FDA, accredited by the American Association of Tissue Banks and is compliant with all applicable state regulations and with the ISO 9001:2008 standard. http://www.allosource.org Presenter: Kevin Cmunt, Executive Vice President, AlloSourceFrom:AllianceRegenMedViews:2 1ratingsTime:14:35More inScience Technology
See more here:
SCMOM 2012_AlloSource - Video
SCMOM 2012_DiscGenics
DiscGenics trade; is a development stage spinal therapeutics company using adult human disc-derived stem cells and tissue engineering techniques to treat patients debilitated by degenerative disc disease (DDD). Back pain is the second most common reason to visit one #39;s doctor, and costs an estimated $100 billion in diagnosis, management, and lost productivity each year. From our patented culture method comes the Discophere trade;, a therapeutic cluster of stem/progenitor cells that have been shown to differentiate and excrete the biological components needed to regenerate an intervertebral disc. http://www.discgenics.com Presenter: Flagg Flanagan, CEO, DiscGenicsFrom:AllianceRegenMedViews:4 1ratingsTime:10:00More inScience Technology
More here:
SCMOM 2012_DiscGenics - Video
SCMOM 2012_Juventas Therapeutics
Juventas Therapeutics is a privately held, clinical-stage biotechnology company developing factor-based regenerative therapies to treat life-threatening diseases. The company #39;s lead product, JVS-100 encodes Stromal cell-Derived Factor-1 (SDF-1) which has been shown to protect and repair tissue following ischemic injury by recruiting the body #39;s own stem cells to the damaged tissue, preventing cell death and promoting new blood vessel growth. Through activating natural stem cell based repair pathways within the patient, we eliminate the cost and complexity associated with current cellular therapies. Juventas is currently enrolling two Phase II clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients. http://www.juventasinc.com Presenter: Rahul Aras, President and CEO, Juventas TherapeuticsFrom:AllianceRegenMedViews:10 1ratingsTime:15:10More inScience Technology
Go here to see the original:
SCMOM 2012_Juventas Therapeutics - Video
Public release date: 15-Oct-2012 [ | E-mail | Share ]
Contact: Veronika Sexl veronika.sexl@vetmeduni.ac.at 43-125-077-2910 University of Veterinary Medicine -- Vienna
So-called Anaplastic Large Cell Lymphoma (ALCL) is even less attractive in real life than it is on paper. It is a highly aggressive type of lymphoma that generally occurs in children and young adults and that has to date proven extremely difficult to treat. It has long been known that ALCL patients frequently show a genetic alteration (a translocation) that causes expression of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a gene known to be capable of giving rise to cancer. But how the NPM-ALK gene works has to date remained largely a matter of conjecture.
Working in a mouse model for lymphoma, Karoline Kollmann in Veronika Sexl's group at the University of Veterinary Medicine, Vienna and colleagues in the Ludwig Boltzmann Institute for Cancer Research and the Medical University of Vienna were able to show that the development of lymphoma is absolutely dependent on the "Platelet derived growth factor receptor B" (PDGFRB), a protein already associated with the growth of other types of tumour. They demonstrated that the effect was direct, with NPM-ALK stimulating the production of the transcription factors JUN and JUNB, which bind to and activate the PDGFRB promoter. And importantly they were able to show that inhibition of PDGFRB with the drug imatinib was able to extend dramatically the survival of mice with this kind of lymphoma.
In human patients, ALCL is traditionally treated with crizotinib, a drug that directly inhibits the NPM-ALK protein. The major problem is that the patients tend to relapse and their chances of survival are extremely poor. Based on the results from the imatinib tests in mice it seemed conceivable that the use of this drug might improve the prognosis of patients who do not or no longer respond to crizotinib therapy. The scientists obtained ethical approval and informed consent to attempt imatinib treatment of an ALCL patient who had not responded to conventional chemotherapy and had relapsed after transplantation of stem cells. Remarkably, the patient improved immediately upon imatinib treatment: after ten days he was in complete remission and he is still alive and again working 22 months later.
The idea of inhibiting PDGFRB in ALCL is novel and potentially of great therapeutic importance. Kollmann is naturally extremely excited by the implications of the results. "The patient had essentially run out of options and would have died a long time ago. But thanks to the indications from our mouse work that inhibiting PDGFRB could prevent growth of this type of tumour he is still alive. This new type of therapy could significantly prolong patient survival."
Intriguingly, the researchers have also found that PDGRFB is also present in ALCL patients without the translocation that leads to NPM-ALK expression. Whether the PDGRFB protein is required for the development of tumours in such patients is not yet clear but it is possible that a combined crizotinib / imatinib therapy might be more widely applicable, providing hope for patients suffering from other types of lymphoma.
The paper "Identification of PDGFR blockade as a rational and highly effective therapy for NPM-ALK driven lymphomas" by Daniela Laimer, Helmut Dolznig, Karoline Kollmann, Paul W. Vesely, Michaela Schlederer, Olaf Merkel, Ana-Iris Schiefer, Melanie R. Hassler, Susi Heider, Lena Amenitsch, Christiane Thallinger, Philipp B. Staber, Ingrid Simonitsch-Klupp, Matthias Artaker, Sabine Lagger, Stefano Pileri, Pier Paolo Piccaluga, Peter Valent, Katia Messana, Indira Landra, Thomas Weichhart, Sylvia Knapp, Medhat Shehata, Maria Todaro, Veronika Sexl, Gerald Hfler, Roberto Piva, Enzo Medico, Bruce A. Riggeri, Mangeng Cheng, Robert Eferl, Gerda Egger, Josef M. Penninger, Ulrich Jaeger, Richard Moriggl, Giorgio Inghirami and Lukas Kenner is published in the current issue of "Nature Medicine". The first four authors contributed equally to the work.
###
Abstract of the scientific article online (full text for a fee or with a subscription): http://dx.doi.org/10.1038/nm.2966
Original post:
Of mice and men
GREEN BAY, WI--A breakthrough in veterinary medicine In Green Bay. Two dogs recover amazingly well after receiving stem cell transplants at Packerland Veterinary Center two months ago. They are the first vet clinic in Wisconsin to perform the procedure.
It's a story that gives hope to pet owners all over the country. Stem cells are taken out of the dog's fatty tissue, harvested, then injected into problem areas leaving the dogs completely healed.
"We couldn't take him on walks. He just laid around a lot," said German Shepherd, DeNiro's owner, Keith Noskowiak.
"We'd hear whimpering overnight. She'd take a few steps and she would sit down," said Luther Kortbein, Shadow's owner, another German Shepherd.
But now the dogs have a whole new life. Until two months ago. DeNiro suffered from severe arthritis.
Shadow. suffered from hip dysplasia. The owners were at their wits end. DeNiro's thought he may even have to put his beloved German Shepherd down.
"We felt we had a decision to make with his quality of life and being in pain we didn't want him to be in pain," said Noskowiak.
Shadow's owner was willing to try anything to cure her.
"Whatever the cost needed to get this done we were willing to do," said Kortbein.
Then Packerland Veterinary Center offered them stem cell therapy. The dog's own stem cells are extracted, then injected back into the bloodstream joints.
Continue reading here:
New Procedure Saves Dogs Lives
With its world-renowned biomedical engineering program, School of Medicine and School of Veterinary Medicine, the University of California, Davis, brings a constellation of expertise to bear on the field of bone regeneration and repair.
Here are some of the UC Davis scientists engaged in bone-repair research:
Professor A. Hari Reddi holds the Lawrence Ellison Chair in Orthopedics at UC Davis. He has studied bone regeneration for more than 40 years and joined the faculty at UC Davis in 1997. His laboratory at the National Institutes of Health was the first to purify bone morphogenetic protein in the 1980s. His laboratory is studying the role of bone morphogenetic proteins in tissue engineering and regeneration of articular cartilage, with an eye toward helping patients with osteoarthritis. Although initially thought of in relation to bone, these proteins are now shown to be involved in brain, cartilage, kidney, lung, tooth and nerve differentiation as well as in heat regulation and iron metabolism, Reddi says. He has proposed changing the name to "body morphogenetic proteins" in view of their versatile role in the human body.
"BMPs are one of the most exciting chapters in modern developmental biology," he says.
More information: http://www.ucdmc.ucdavis.edu/ctrr/research/reddi.html
Understanding the healing and regeneration of cartilage is the aim of the Musculoskeletal Bioengineering Laboratory led by Professor Kyriacos Athanasiou, chair of the Department of Biomedical Engineering at UC Davis. Cartilage forms the hard covering at the ends of bones. Tissues such as the knee meniscus have to deal with demanding loads but show little or no ability to regenerate by themselves.
Athanasiou's lab aims to understand the healing processes of cartilage, and to augment those processes through tissue engineering. Their approach uses both biomechanical techniques and bioactive agents and signals. They are also interested in stem cell technologies to repair cartilage and connective tissue.
The team has partnered with surgeons at the UC Davis Veterinary Medical Teaching Hospital to regrow jawbones for dogs that have lost part of their jaw due to cancer or injury. The technique uses a sponge-like scaffolding impregnated with bone morphogenetic protein, which is inserted into the space where the bone was removed. The growth-promoting protein stimulates the dogs remaining jawbone to grow new bone cells, eventually filling the entire defect and integrating with the native bone.
More information: http://www.bme.ucdavis.edu/athanasioulab/
Kent Leach, associate professor of biomedical engineering, is working with matrix materials that encourage the growth of new bone from stem cells. With funding from The Hartwell Foundation, he is working on treatments that could be used in babies with craniosynostosis, a condition where the bones of the skull fuse too early. In a project funded by the U.S. Department of Defense, Leach is studying a gel-like matrix that can be seeded with adult stem cells from fat and used to heal bone fractures more rapidly.
See the original post:
Bone repair research at UC Davis
Public release date: 24-Apr-2012 [ | E-mail | Share ]
Contact: Dr Boris Kovacic Boris.Kovacic@vetmeduni.ac.at 43-125-077-5622 University of Veterinary Medicine -- Vienna
Although people generally talk about "cancer", it is clear that the disease occurs in a bewildering variety of forms. Even single groups of cancers, such as those of the white blood cells, may show widely differing properties. How do the various cancers arise and what factors determine their progression? Clues to these two issues, at least for leukaemias, have now been provided by Boris Kovacic and colleagues at the University of Veterinary Medicine, Vienna (Vetmeduni Vienna). The results are published in the current issue of the journal EMBO Molecular Medicine and have extremely important consequences for the treatment of a particularly aggressive type of leukaemia.
It is well known that many types of cancer arise as a result of a mutation within a cell and prevailing wisdom has held that the stage of differentiation of this cell determines exactly what form of cancer develops. For example, it was believed that so-called chronic myeloid leukaemia or CML arises from bone marrow stem cells, while a different type of leukaemia, known as B-cell acute lymphoid leukaemia or B-ALL, results from B-cell precursors. This belief has been spectacularly refuted by the latest results from Boris Kovacic and colleagues in the Vetmeduni Vienna's institutes of Animal Breeding and Genetics and of Pharmacology and Toxicology.
The researchers have now shown that both CML and B-ALL arise from the most primordial kind of blood cell (long-term haematopoietic stem cells), although the pathways by which the diseases progress are different. The usual causes of CML and B-ALL are two highly related versions of the same oncogene, BCR/ABL. If the primordial blood cells are transformed or made potentially cancerous by a particular version of BCR/ABL, for technical reasons termed BCR/ABLp210, the result is chronic myeloid leukaemia or CML. The long-term haematopoietic stem cells remain and act as the dreaded cancer stem cells, or CSCs, which ensure that the disease persists. Curing chronic myeloid leukaemia requires the complete elimination of the CSCs. However, if the long-term haematopoietic stem cells are transformed by a related version of BCR/ABL, BCR/ABLp185, the result is a highly aggressive form of leukaemia, B-ALL. The finding that B-ALL actually originates from the same stem cells as CML was both unexpected and highly provocative.
Kovacic and colleagues have shown further that B-ALL only develops if the transformed stem cell is exposed to a particular growth factor, interleukin-7. If interleukin-7 is present (it usually is), the transformed long-term haematopoietic stem cells undergo a differentiation step to CSCs, which in this case correspond to pro-B cells. If interleukin-7 is absent during the initial phase of transformation, B-ALL cannot develop.
In other words, two distinct types of cell are involved in leukaemia development, the primordial cells (also termed the cells of origin of cancer) and the cancer stem cells that cause the disease to progress. Unless the CSCs are eliminated, fresh cancer cells can arise at any time and the leukaemia will recur. The problem is that current leukaemia therapies are not designed to target CSCs. The primordial CSCs in CML are highly quiescent and thus difficult to target. In contrast, the CSCs in B-ALL are abundant and have a high turnover rate, which makes them susceptible to treatment. Treatment of B-ALL may thus succeed in eliminating most CSCs but if even a single cell remains intact it is likely that the patient will relapse, possibly with an even more aggressive form of leukaemia. "A therapy that targets the bulk of tumour cells will not work," as Kovacic succinctly summarizes his results. "To treat B-ALL successfully it will be necessary for us to learn much more about the development of the disease. A combined therapy is required, so future work should aim at developing drugs that target the long-term haematopoietic stem cells from which B-ALL is derived."
###
The paper "Diverging fates of cells of origin in acute and chronic leukemia" by Boris Kovacic, Andrea Hoelbl, Gabriele Litos, Memetcan Alacakaptan, Christian Schuster, Katrin M. Fischhuber, Marc A. Kerenyi, Gabriele Stengl, Richard Moriggl, Veronika Sexl and the late Hartmut Beug is published in the current issue of the journal "EMBO Molecular Medicine" (2012, Vol. 4 pp. 283-297).
The work was initiated at the Research Institute of Molecular Pathology (IMP) and was performed together with groups at the Medical University of Vienna and the Ludwig Boltzmann Institute for Cancer Research in Vienna.
Read more here:
Leukaemia cells have a remembrance of things past
Public release date: 28-Mar-2012 [ | E-mail | Share ]
Contact: Evan Lerner elerner@upenn.edu 215-573-6604 University of Pennsylvania
PHILADELPHIA Treatments for childhood cancers are increasingly successful with cure rates approaching 80%, but success often comes with a downside for the surviving men: the cancer treatments they received as boys can leave them sterile as adults. Now, a research team led by Ralph Brinster of the University of Pennsylvania School of Veterinary Medicine has completed a 14-year experiment that gives hope for a technique that could restore their fertility.
Brinster is the Richard King Mellon Professor of Reproductive Physiology at Penn Vet and was recently awarded the National Medal of Science for his lifetime of research on the genetics of the mammalian germline, the cells that give rise to sperm and eggs.
In his most recent research, Brinster collaborated with fellow members of the Department of Animal Biology at Penn Vet, with members of the Department of Cell and Developmental Biology at Penn's Perelman School of Medicine and with the Penn Bioinformatics Core.
Their study was published in the journal Human Reproduction.
For males, fertility begins with spermatogonial stem cells, which are present at birth, embedded in the basement membrane of the testes' seminiferous tubules. As a boy approaches puberty, these cells begin to make daughter cells that eventually become sperm. While they normally continue this process throughout a post-pubescent man's life, factors like radiation and chemotherapy drugs can destroy them, rendering him sterile.
About 1 in 3 boys surviving childhood cancer will be in danger of having severely decreased fertility as an adult; as many as 1 in 5,000 men of reproductive age currently suffer this serious quality-of-life problem as a result. Adult men who undergo cancer treatment that might damage their fertility can preemptively freeze their sperm, an option not available to pre-pubescent boys. But if a sample of a boy's spermatogonial stem cells could be extracted and preserved before cancer treatment and re-implanted after the boy reached adulthood, this fertility problem could be circumvented.
"There are a number of places, including at the Children's Hospital of Philadelphia," Brinster said, "that are already freezing cells for patients to use later, with the expectation that the necessary culture system and implantation techniques will be developed. A logical question for patients to ask is, How do we know that, after 10 years or more of being stored, these cells are any good? That's what our study addresses."
The techniques for extracting these cells and re-implanting them have been developed, so a critical question for researchers was whether spermatogonial stem cells could survive the decade-plus period they might need to remain frozen.
Read more:
Penn research points to new way of preserving fertility for boys undergoing cancer treatment
24-02-2012 17:04 Dr.Mark Newkirk is once again on the cutting edge of medicine. Newkirk Family Veterinarians now offer STEM CELL THERAPY for pets. Dr. Mark Newkirk combines traditional medicine and surgery with Holistic Alternatives to access the best of both worlds. As a Veterinarian, Dr. Newkirk has been serving Southern New Jersey for over 25 years. He is extensively trained in medicine and surgery and also is skilled in the care of exotic pets such as reptiles and birds. Dr. Newkirk is also one of only 5 doctors in the country currently undergoing training by the nationally renowned Dr. Martin Goldstein, the author of "The Nature of Animal Healing", and founder of immuno-augmentative therapy for animals, a true alternative cancer therapy. Dr. Newkirk is a member of American Holistic Veterinary Medical Society, the American Veterinary Medical Association, New Jersey Veterinary Medical Association and the Colorado Veterinary Medical Association. For more information check out Stem Cell Therapy on The Animal Planet's dogs 101 http://www.youtube.com
Go here to read the rest:
Stem Cell Therapy at Newkirk Family Veterinarians - Hunter's Story - Video
Scientists grow a rat lung in the laboratory
By LAURAN NEERGAARD (AP) – 4 days ago
WASHINGTON — It's an early step toward one day building new lungs: Yale University researchers took apart and regrew a rat's lung, and then transplanted it and watched it breathe.
The lung stayed in place only for an hour or two, as the scientists measured it exchanging oxygen and carbon dioxide much like a regular lung — but also spotted some problems that will take more research to fix.
Still, the work is a step in the science fiction-sounding hunt for ways to regenerate damaged lungs — although lead researcher Dr. Laura Niklason cautions that it may be 20 or 25 years before a build-a-new-organ approach is ready for people.
The work was reported online Thursday in the journal Science.
Nearly 400,000 people die of lung diseases each year in the U.S. alone, according to the American Lung Association, and lung transplants are far too rare to offer much help.
But how to replicate these spongy organs? Niklason's team stripped an adult rat's lung down to its basic structural support system — its scaffolding — to see if it's possible to rebuild rather than starting completely from scratch.
First, they essentially washed away the different kinds of cells lining that lung. It gradually faded from a healthy red to a white structure of mostly collagen and other connective tissue that maintained the shape and stretchiness of the original lung, even the tubes where airways would be.
This scaffolding is like a universal donor that shouldn't pose rejection problems, said Niklason: "Your collagen and my collagen are identical."
The researchers put the lung scaffolding into a bioreactor, an incubator-style container designed to mimic the environment in which fetal lungs develop, with fluid pumping through them.
Then they injected a mixture of different lung cells taken from a newborn rat. In the bioreactor, those cells somehow migrated to the right spots and grew air sacs, airways and blood vessels.
In short-term implants in four different rats, engineered lungs replaced one of the animals' native lungs and proved 95 percent as efficient at exchanging oxygen and carbon dioxide, Niklason said.
However, among the problems she spotted were small clots that formed inside the engineered lung, a sign that the new cells hadn't grown a thick enough cover in some places.
The biggest challenge: For this approach ever to work without a person's body rejecting the new tissue, scientists would need to use a recipient's own cells, Niklason explained. But there isn't a way yet to cull the kind of personalized stem cells that would be needed, meaning stem cell research must improve first, she said.
This overall approach also worked in a 2008 University of Minnesota experiment that grew a beating rat heart, and Minnesota researcher Dr. Doris Taylor welcomed the Yale lung work.
Separately in Science, a Harvard University team coated a flexible chip with layers of living lung cells, creating a laboratory tool that mimics some of the action of a breathing human lung. The goal: To replace some of the animal studies needed to test how lungs react to environmental toxins or inhaled drugs.
Online: http://www.sciencemag.org
At three years old, Justin, a German Shepherd-cross, seems too young to be afflicted with osteoarthritis.
But his early life, marred by abuse, left Justin with arthritis, hip dysplasia, flesh-eating disease and a cracked molar. “He is a big mess. A lot of people would euthanize him, but I don’t want to give up on him,” said Jamie Lee, a Vancouverite who adopted Justin nine months ago from an animal rescue group.
The mission to relieve Justin’s pain brought Ms. Lee to the frontier of veterinary medicine: stem-cell therapy.
It’s one of the holistic practices, including raw food, acupuncture and massage, showcased at The Petnership Project Tradeshow and Lecture Series in Vancouver on Saturday.
Justin broke one of his legs as a puppy, but his owners never took him to the vet. The injury resulted in osteoarthritis that spread to his other limbs.
The specialist said they could try an implant to relieve the pain, but there was a high risk that failure could lead to amputation, Ms. Lee said.
Instead, Ms. Lee decided to try an innovative treatment called stem-cell therapy, a procedure that extracts cells from the animal’s fat and moves them into the injured area to jump-start healing.
The procedure took less than 48 hours, even though the fat was shipped to a San Diego-based company called Vet-Stem. The company extracts cells from the fat tissue and sends back a needle to be inserted into the pet’s source of pain.
Ms. Lee said Justin’s mobility has gradually increased by 50 per cent after the surgery. Now the pooch, who could barely walk, can stroll for an easy 30 minutes.
But pain relief doesn’t come cheap: Ms. Lee spent around $4,000 to get treatment for all four of Justin’s joints.
The average treatment cost runs between $1,200 and $1,500, said Loridawn Fawcett of Vancouver’s The Healing Place, who advised Justin’s treatment. The treatment only has to be done once, unless there is a new injury, she said.
Results can take up to three months, said Dr. Fawcett, adding the success rate is 80 per cent.
Most dogs have the therapy to treat arthritis, but it can help heal fractures, tendon-ligament injuries and liver disease, said Dr. Fawcett.
This therapy goes beyond stem-cell treatments available for humans in Canada, which require adult stem cells to be taken from a donor’s bone marrow. Research into whether humans can successfully harvest and use their own stem cells for regenerative therapy is ongoing, but is not yet approved.
While it may be exciting, Thomas Koch of the Ontario Veterinary College cautions the science behind the therapy is not proven. The cells may have a therapeutic effect, he said, but scientists don’t know exactly how or why.
“The marketing is trumping the science and it’s obviously feeding off the hope and hype in the whole area of regenerative medicine,” said Dr. Koch. Still, the procedure seems safe in terms of infection because patients are receiving their own cells, he said, adding that there is still a risk people are paying for ineffective therapy.
It was worth it for Justin, said Ms. Lee.
She advises other pet owners considering the option to do some research, get a full blood test and consult with their vet about whether stem cell therapy is the right choice for their pet.
“If something goes wrong in surgery, you cannot go back,” said Ms. Lee. “With stem-cell therapy, what’s the worst that can happen? You pay more money.”